A carregar...
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure
BACKGROUND: Tipranavir (TPV) is a recently approved nonpeptidic protease inhibitor (PI) of HIV-1 and has been indicated for those infected with PIs-resistant HIV-1. However, in clinical practice, whether the HIV-1 from the patients with virological failure to the regimens containing first-line PIs r...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2749855/ https://ncbi.nlm.nih.gov/pubmed/19751502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-9-154 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|